Showing posts from December, 2023Show all
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint health-issue

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Nitesh sinha December 20, 2023

https://ift.tt/os9kIx3 Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoi…

Read more
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa health-issue

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

Nitesh sinha December 15, 2023

https://ift.tt/mFePvaq   from Sanofi - Aventis Groupe https://ift.tt/3Npy0tz via IFTTT

Read more
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics health-issue

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Nitesh sinha December 11, 2023

https://ift.tt/eY2VpqD from Sanofi - Aventis Groupe https://ift.tt/qUx9Cjr via IFTTT

Read more
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone health-issue

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

Nitesh sinha December 10, 2023

https://ift.tt/WhUJOou from Sanofi - Aventis Groupe https://ift.tt/eKjVlJE via IFTTT

Read more
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant health-issue

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

Nitesh sinha December 07, 2023

https://ift.tt/RnGcMUB Sarclisa ® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed mult…

Read more
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology health-issue

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

Nitesh sinha December 06, 2023

https://ift.tt/4xvnado R&D Day from Sanofi - Aventis Groupe https://ift.tt/3KMTzsa via IFTTT

Read more